Stock Events

Stock Events

Janux Therapeutics 

$19.80
44
+$0.10+0.51% Thursday 20:00
+$0.00+0%Thursday 23:59After hours

Statistics

Day High
19.85
Day Low
19.75
52W High
35.34
52W Low
12.12
Volume
42,791
Avg. Volume
-
Mkt Cap
1.21B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.61
-0.49
-0.37
-0.25
Expected EPS
-0.473915
Actual EPS
N/A

Financials

-1,136.25%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
10MRevenue
-113.63MNet Income

Analyst Ratings

29.71Average Price Target
The highest estimate is 55.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
86%
Hold
0%
Sell
14%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow JANX. It's not an investment recommendation.
NVIDIA
10
NVDA
Amazon
9
AMZN
Microsoft
8
MSFT
Tesla
7
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that operates in the same oncology space, competing with Janux Therapeutics in developing cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines in areas including oncology, competing directly with Janux Therapeutics.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology company focused on human therapeutics, including oncology, which puts it in direct competition with Janux Therapeutics.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. focuses on antiviral drugs and cancer therapies, making it a competitor in the oncology sector alongside Janux Therapeutics.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is a global biopharmaceutical company with a strong emphasis on oncology, competing with Janux Therapeutics in cancer drug development.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a major player in the pharmaceutical and diagnostics world, with a significant focus on oncology, competing with Janux Therapeutics.
Novartis
NVS
Mkt Cap292.35B
Novartis AG focuses on patented medicines, including those for cancer, making it a direct competitor to Janux Therapeutics in the oncology field.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC is a global, science-led biopharmaceutical business that operates in the same therapeutic areas as Janux Therapeutics, including oncology.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biotechnology, including oncology, competing with Janux Therapeutics in developing cancer treatments.

About

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Show more...
CEO
David Alan Campbell
Employees
113
Country
United States
ISIN
US47103J1051

Listings

XNAS
US
JANX
BOATS
BOATS
JANX.BOATS

0 Comments

Share your thoughts

FAQ

What is Janux Therapeutics stock price today?▼
The current price of JANX is $19.80 USD — it has increased by +0.51% in the past 24 hours. Watch Janux Therapeutics stock price performance more closely on the chart.
What is Janux Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Janux Therapeutics stocks are traded under the ticker JANX.
Is Janux Therapeutics stock price growing?▼
JANX stock has risen by +9.82% compared to the previous week, the month change is a +24.06% rise, over the last year Janux Therapeutics has showed a -17.29% decrease.
What is Janux Therapeutics market cap?▼
Today Janux Therapeutics has the market capitalization of 1.21B
When is the next Janux Therapeutics earnings date?▼
Janux Therapeutics is going to release the next earnings report on November 10, 2026.
What were Janux Therapeutics earnings last quarter?▼
JANX earnings for the last quarter are -0.35 USD per share, whereas the estimation was -0.25 USD resulting in a -39.28% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Janux Therapeutics revenue for the last year?▼
Janux Therapeutics revenue for the last year amounts to 10M USD.
What is Janux Therapeutics net income for the last year?▼
JANX net income for the last year is -113.63M USD.
How many employees does Janux Therapeutics have?▼
As of September 04, 2026, the company has 113 employees.
In which sector is Janux Therapeutics located?▼
Janux Therapeutics operates in the Health & Wellness sector.
When did Janux Therapeutics complete a stock split?▼
Janux Therapeutics has not had any recent stock splits.
Where is Janux Therapeutics headquartered?▼
Janux Therapeutics is headquartered in SAN DIEGO, United States.